Overview Technical Risk & rank Results Accounts Filings Options Guidance & governance
Filings
41 filings of PPLPHARMA since January 2025; the newest 40 below.
presentation 12, board outcome 11, transcript 8, results 3, acquisition 3, dividend 2
| Filed | Type | Subject | |
|---|---|---|---|
| 30 Oct 2026 | transcript | Piramal Pharma Limited has informed the Exchange about TranscriptAI summaryPiramal Pharma Limited filed the transcript of its conference call held on 28 October 2026 on the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. The transcript is available on the company's website at https://www.piramalpharma.com/financial-reports. The filing is a cover letter under Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015; the pages provided do not include the call content or figures. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2026 | presentation Guidance, Results | Piramal Pharma Limited has informed the Exchange about PresentationAI summaryPiramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026 (Q2 and H1 FY27). Consolidated revenue from operations was ₹2,617 crores in Q2FY27 (up 28% YoY from ₹2,044 crores) and ₹4,887 crores in H1FY27 (up 23% YoY); EBITDA was ₹385 crores in Q2FY27 (up 72%) with EBITDA margin of 14.7%, and PAT was ₹5 crores in Q2FY27 versus a loss of ₹99 crores a year earlier. Management said it upgraded its FY27 outlook and now expects revenue growth of 19% to 20%, with meaningfully higher profitability. Management said the Bayer distribution agreement in the consumer healthcare business will naturally expire in December 2026, with no material impact expected on FY27 guidance. An earnings conference call is scheduled for 28 October 2026 from 10:00 AM to 10:45 AM IST. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2026 | presentation Guidance, Results | Piramal Pharma Limited has informed the Exchange about Investor PresentationAI summaryPiramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for Q2 and H1 FY27 (quarter and half year ended 30 September 2026). Consolidated revenue from operations was ₹2,617 crores in Q2FY27 (up 28% YoY from ₹2,044 crores) and ₹4,887 crores in H1FY27 (up 23% YoY); EBITDA was ₹385 crores in Q2FY27 (up 72%) and ₹669 crores in H1FY27 (up 72%). Consolidated PAT was ₹5 crores in Q2FY27 against a loss of ₹99 crores in Q2FY26, and a loss of ₹64 crores in H1FY27 against a loss of ₹181 crores in H1FY26. Management upgraded its FY27 outlook to revenue growth of 19% to 20%, with meaningfully higher profitability. Management said the Bayer distribution agreement in PCH will naturally expire in December 2026, with no material impact expected on FY27 guidance. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2026 | board outcome Results | Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryPiramal Pharma Limited filed the outcome of its board meeting held on 27 October 2026, approving unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. Standalone revenue from operations for the quarter ended 30 September 2026 was Rs 1,345.38 crores, against Rs 1,127.26 crores in the corresponding quarter of the previous year. Standalone net profit after tax for the quarter was Rs 170.74 crores, against Rs 196.33 crores in the corresponding quarter of the previous year. Standalone basic EPS for the quarter was Rs 1.29, and for the half year ended 30 September 2026 it was Rs 2.14. The filing includes limited review reports by the statutory auditors; it does not contain management commentary on the outlook. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Aug 2026 | acquisition Acquisition | Piramal Pharma Limited has informed the Exchange about AcquisitionAI summaryPiramal Pharma Limited disclosed under Regulation 30 of the SEBI Listing Regulations that it has completed the acquisition of 1,46,400 equity shares of ₹10 each of Yapan Bio Private Limited from existing shareholders for an aggregate cash consideration of approximately ₹76 crores. The Company's shareholding in Yapan has increased from 33.33% to 74.00% of its equity share capital, and Yapan has ceased to be an associate and become a subsidiary of the Company. Yapan, incorporated on 11 October 2019, is a Contract Development and Manufacturing Organization for process development, characterization and Phase I/II GMP manufacturing of vaccines and biologics. Yapan's revenue from operations was ₹26.91 crores in FY2024, ₹54.40 crores in FY2025 and ₹26.34 crores in FY2026. Management said the acquisition will embed Yapan's large molecule capabilities into the Company's integrated service offering to develop and scale complex biologic therapies. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 Jul 2026 | transcript | Piramal Pharma Limited has informed the Exchange about TranscriptAI summaryPiramal Pharma Limited filed the transcript of its conference call held on 30 July 2026 on the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. The filing states that the transcript is available on the company's website at piramalpharma.com/financial-reports. The filing itself contains no financial figures, outlook or management commentary from the call. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jul 2026 | presentation Results | Piramal Pharma Limited has informed the Exchange about PresentationAI summaryPiramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter ended 30 June 2026 (Q1 FY27). Consolidated revenue from operations rose 17% year-on-year to ₹2,270 crores; EBITDA rose 72% to ₹285 crores, with EBITDA margin at 12.5% versus 8.5%. Loss after tax before exceptional item narrowed to ₹(69) crores from ₹(102) crores; Q1 FY26 included a ₹21 crore exceptional item (insolvency proceeds). Management said all three businesses delivered mid-to-high teens revenue growth and it looks forward to sustained revenue growth and EBITDA expansion through FY27, while staying agile amid a dynamic external environment. An earnings conference call is scheduled for 30 July 2026, 9:30 AM to 10:15 AM IST. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jul 2026 | presentation Guidance, Results | Piramal Pharma Limited has informed the Exchange about Investor PresentationAI summaryPiramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter ended 30 June 2026 (Q1 FY27). Consolidated revenue from operations rose 17% to ₹2,270 crores (Q1 FY26: ₹1,934 crores); EBITDA rose 72% to ₹285 crores, with EBITDA margin at 12.5% (8.5% previously). Consolidated PAT before exceptional item was a loss of ₹69 crores (loss of ₹102 crores in Q1 FY26); PAT after exceptional item was a loss of ₹69 crores (loss of ₹82 crores in Q1 FY26). Chairperson Nandini Piramal said management expects sustained revenue growth and EBITDA expansion through FY27, while staying agile amid a dynamic external environment. Management said CDMO customer decision-making timelines remain prolonged despite increased RFPs; the company will hold an earnings call on 30 July 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jul 2026 | board outcome Results | Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryPiramal Pharma Limited's board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 at its meeting held on July 29, 2026. Standalone revenue from operations for Q1 FY27 was Rs. 1,124.95 crore, against Rs. 969.88 crore in the June 30, 2025 quarter and Rs. 1,489.06 crore in the March 31, 2026 quarter. Standalone net profit after tax for the quarter was Rs. 113.48 crore, against Rs. 113.14 crore a year earlier; basic EPS was Rs. 0.85. The statutory auditors carried out a limited review of the results; the company stated there were no exceptional items in the quarter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Apr 2026 | transcript | Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026AI summaryPiramal Pharma Limited filed the transcript of its conference call held on 29 April 2026 on the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026. The transcript is available on the company's website at piramalpharma.com/financial-reports, as filed under Regulation 30(6) of the SEBI Listing Regulations. The filing covers only the transcript availability notice; the call content and figures are not included in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Apr 2026 | presentation Acquisition, Capex, Guidance, Results | Piramal Pharma Limited has informed the Exchange about Investor PresentationAI summaryPiramal Pharma Limited filed its press release and investor presentation on audited standalone and consolidated results for the quarter and year ended 31 March 2026. Q4FY26 consolidated revenue from operations was ₹2,752 Crores (flat YoY) and EBITDA was ₹507 Crores (down 16% YoY, margin 18%). Q4FY26 PAT after exceptional item was ₹(9) Crores, after a ₹176 Crores impairment on intangible assets under development. FY26 consolidated revenue from operations was ₹8,869 Crores (down 3% YoY), EBITDA was ₹1,135 Crores (down 28%), and PAT after exceptional item was ₹(326) Crores. Management said FY26 was a transitional year and that all three businesses are well positioned to deliver growth in FY27, with accelerated growth in EBITDA and PAT. Management also cited completion of the Kenalog acquisition (upfront US$35Mn, contingent up to US$65Mn), US$94Mn capex in FY26, and net debt of ₹4,140 Crores versus ₹4,199 Crores at 31 March 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Apr 2026 | board outcome Legal, Management change, Results | Piramal Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 28, 2026.AI summaryBoard of Piramal Pharma Limited approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, with auditor reports carrying an unmodified opinion (auditor: Suresh Surana & Associates LLP). Board re-appointed Ms. Nandini Piramal as Whole-Time Director designated as Executive Director and Chairperson for 3 years from 1 April 2027, and Mr. Peter DeYoung as Whole-Time Director designated as Executive Director for 3 years from 6 October 2026, both subject to shareholder approval. Board re-appointed Mr. Sridhar Gorthi and Mr. Peter Stevenson as Non-Executive Independent Directors for a second term of 5 years from 30 March 2027, subject to shareholder approval; Mr. Stevenson's continuation beyond age 75 was also approved. Board appointed Mr. Maneesh Sharma as Company Secretary and Compliance Officer (KMP) effective 29 April 2026, replacing interim Company Secretary Ms. Pratibha Mishra. Board approved a change in registered office address to Ananta Building, Piramal Corporate Park, Kurla (West), Mumbai, effective 30 April 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Apr 2026 | board outcome Legal, Management change, Results | Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryBoard of Piramal Pharma Limited approved audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026; the statutory auditor (Suresh Surana & Associates LLP) issued unmodified opinions. Board approved re-appointment of Ms. Nandini Piramal as Whole-Time Director designated as Executive Director and Chairperson for 3 years from 1 April 2027, and of Mr. Peter DeYoung as Whole-Time Director designated as Executive Director for 3 years from 6 October 2026, both subject to shareholder approval. Board approved second terms of 5 consecutive years from 30 March 2027, subject to shareholder approval, for Mr. Sridhar Gorthi and Mr. Peter Stevenson as Non-Executive, Independent Directors. Board approved appointment of Mr. Maneesh Sharma as Company Secretary and Compliance Officer (KMP) with effect from 29 April 2026; Ms. Pratibha Mishra ceases as Interim Company Secretary. Board approved change of registered office address to Ananta Building, Piramal Corporate Park, Kamani Junction, Kurla (West), Mumbai, effective 30 April 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2026 | transcript Results | Piramal Pharma Limited has informed the Exchange about TranscriptAI summaryPiramal Pharma Limited filed the transcript of its conference call held on 29 January 2026 on the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025. The transcript is available on the company's website at piramalpharma.com/financial-reports. The filing itself contains no financial figures or management commentary; the call content is not reproduced in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jan 2026 | presentation Acquisition, Capex, Guidance, Results | Piramal Pharma Limited has informed the Exchange about Investor PresentationAI summaryPiramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2025. Consolidated Q3FY26 revenue from operations was ₹2,140 crore (down 3% YoY from ₹2,204 crore); 9MFY26 revenue was ₹6,117 crore (down 4% YoY). Consolidated Q3FY26 EBITDA was ₹239 crore (down 32% YoY) with margin of 11%; Q3FY26 PAT after exceptional item was a loss of ₹136 crore versus profit of ₹4 crore in Q3FY25. Management said FY26 has been a muted year due to inventory destocking and slower early-stage order inflows in the CDMO business, but early signs of recovery are seen with a pick-up in RFPs and order inflows since October 2025. The company agreed to acquire Kenalog from Bristol-Myers Squibb for US$35 million upfront plus up to US$65 million contingent consideration, and has a US$90 million growth capex plan for Lexington and Riverview facilities. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jan 2026 | board outcome Results | Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryPiramal Pharma Limited filed the outcome of its board meeting held on 28 January 2026, approving unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025. Standalone revenue from operations for Q3 FY26 was Rs 1,195.81 crores, against Rs 1,248.32 crores a year earlier; net profit after tax was Rs 128.91 crores, against Rs 118.80 crores. Q3 FY26 profit before tax of Rs 154.93 crores includes an exceptional charge of Rs 26.94 crores from the new Labour Codes, which the company says is regulatory-driven and non-recurring. Nine-month standalone revenue from operations was Rs 3,292.95 crores, against Rs 3,595.91 crores a year earlier; diluted EPS for the quarter was Rs 0.97. The statutory auditors, Surana & Associates LLP, issued a limited review report with no material misstatement noted. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | transcript Results | Piramal Pharma Limited has informed the Exchange about TranscriptAI summaryPiramal Pharma Limited filed the transcript of its conference call held on 6 November 2025 on the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025. The transcript is available on the company's website at piramalpharma.com under financial reports. The filing itself contains no financial figures, guidance or management commentary in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2025 | presentation Results | Piramal Pharma Limited has informed the Exchange about Investor PresentationAI summaryPiramal Pharma Limited filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter and half year ended 30 September 2025. Consolidated revenue from operations was ₹2,044 crores in Q2FY26, down 9% YoY from ₹2,242 crores, and ₹3,977 crores in H1FY26, down 5% YoY; management attributed the decline mainly to inventory destocking by a customer in one large CDMO order. Consolidated EBITDA was ₹224 crores in Q2FY26 (down 44% YoY, margin 11%) and ₹389 crores in H1FY26 (down 38%, margin 10%); consolidated PAT was a loss of ₹99 crores in Q2FY26 and a loss of ₹181 crores in H1FY26 (after exceptional item). Net debt was ₹3,971 crores at 30 September 2025, reduced by ₹228 crores versus FY25, with net debt to EBITDA maintained below 3x. Chairperson Nandini Piramal said US biopharma funding recovery was inconsistent in H1FY26 and trade policy uncertainty affected order inflows, but biopharma funding picked up in September and October 2025; CHG and consumer business commentary was also given. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2025 | board outcome Results | Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryPiramal Pharma Limited's board approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025 at a meeting held on 5 November 2025, with limited review reports from statutory auditors enclosed. Standalone revenue from operations for the quarter ended 30 September 2025 was Rs 1,127.26 crores, against Rs 969.88 crores in the June 2025 quarter and Rs 1,284.39 crores in the September 2024 quarter. Standalone net profit after tax for the quarter was Rs 196.33 crores, against Rs 113.14 crores in the June 2025 quarter and Rs 210.06 crores in the September 2024 quarter. Standalone basic EPS for the quarter was Rs 1.48 (not annualised), against Rs 1.59 in the September 2024 quarter. Year-to-date standalone revenue from operations for the half year was Rs 2,097.14 crores, against Rs 2,347.59 crores in the corresponding prior period. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 Oct 2025 | credit rating Rating | Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Withdrawal of Credit Rating.AI summaryPiramal Pharma Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations on 16 October 2025. ICRA Limited withdrew the credit rating of [ICRA]A1+ assigned to the Company's Rs. 100 crore Commercial Paper Programme (proposed), at the Company's request. The withdrawal is because there is no open issue of Commercial Paper, and follows ICRA's policy on withdrawal of ratings. The ICRA press release is dated 15 October 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 Aug 2025 | acquisition Acquisition | Piramal Pharma Limited has informed the Exchange about Completion of AcquisitionAI summaryPiramal Pharma Limited filed under Regulation 30 of the SEBI Listing Regulations, referring to its intimation dated April 23, 2025. Its material step-down wholly owned subsidiary, Piramal Healthcare Inc., has completed subscription of 1,903 optionally convertible redeemable preference shares of face value USD 100,000 each in PPL Pharma Inc., another step-down wholly owned subsidiary. The subscription aggregates USD 190,300,000 (₹ 1,626.49 Crore). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 Jul 2025 | transcript Results | Piramal Pharma Limited has informed the Exchange about TranscriptAI summaryPiramal Pharma Limited filed the transcript of its conference call held on 29 July 2025 on the unaudited standalone and consolidated financial results for the quarter ended 30 June 2025. The filing states the transcript is available on the company's website at piramalpharma.com/financial-reports. The pages provided do not include the call content, so no management commentary or financial figures are stated here. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jul 2025 | presentation Guidance, Legal, Results | Piramal Pharma Limited has informed the Exchange about Investor PresentationAI summaryPiramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter ended 30 June 2025 (Q1FY26). Consolidated revenue from operations was ₹1,934 crore vs ₹1,951 crore in Q1FY25 (down 1%); EBITDA was ₹165 crore vs ₹224 crore (down 26%), with EBITDA margin at 9% vs 11%. Consolidated net loss after tax (after exceptional item) was ₹82 crore vs ₹89 crore in Q1FY25; net debt to EBITDA was 2.6x. Management said CDMO base business grew mid-teens excluding destocking in one large on-patent product, and that it remains on track for its FY2030 aspirations of a US$2bn revenue company with 25% EBITDA margin and high-teen ROCE. Management expects CHG growth to pick up for the rest of the year and intrintrathecal therapy growth to recover in Q2FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jul 2025 | presentation Capex, Guidance, Results | Piramal Pharma Limited has informed the Exchange regarding a press release dated July 28, 2025, titled "Press Release and Investor Presentation Unaudited Financial Results(Standalone & Consolidated) of the Company for the quarter ended 30thAI summaryPiramal Pharma Limited filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter ended 30 June 2025 (Q1FY26). Consolidated revenue from operations was ₹1,934 crores vs ₹1,951 crores in Q1FY25 (down 1%); EBITDA was ₹165 crores vs ₹224 crores, with EBITDA margin at 9% vs 11%; PAT after exceptional item was reported as ₹(82) crores vs ₹(89) crores. Management (Chairperson Nandini Piramal) said that excluding destocking in one large on-patent CDMO product, the CDMO business delivered mid-teen revenue growth, and that the consumer business grew in line with expectations. Management said it believes it is on track for its FY2030 aspirations of a US$2bn revenue company with 25% EBITDA margin and high-teen ROCE, while facing near-term challenges. A earnings conference call was scheduled for 29 July 2025 from 9:30 AM to 10:15 AM IST. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jul 2025 | board outcome Results | Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryPiramal Pharma Limited's board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, on July 28, 2025, with Limited Review Reports from the statutory auditors enclosed. Standalone revenue from operations for the quarter ended June 30, 2025 was Rs. 969.88 crore, against Rs. 1,063.20 crore in the corresponding quarter last year and Rs. 1,689.80 crore in the March 31, 2025 quarter. Standalone other income for the quarter was Rs. 180.92 crore, and profit before tax was Rs. 142.58 crore. Standalone net profit after tax for the quarter was Rs. 113.14 crore, against Rs. 85.27 crore in the corresponding quarter last year; basic EPS was Rs. 0.85. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jul 2025 | board outcome Results | Outcome of Board Meeting of Piramal Pharma Limited ( Company ) held on 28th July, 2025 - Financial ResultsAI summaryPiramal Pharma Limited's board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 at its meeting held on July 28, 2025. Standalone revenue from operations for Q1 FY26 was Rs. 969.88 crores, against Rs. 1,063.20 crores in the corresponding quarter last year and Rs. 1,689.80 crores in the March 2025 quarter. Standalone net profit after tax for the quarter was Rs. 113.14 crores, against Rs. 85.27 crores a year earlier; other income (net) was Rs. 180.92 crores. Basic EPS for the quarter was Rs. 0.85, against Rs. 0.64 in the corresponding quarter last year. The statutory auditors, Deloitte Haskins & Sells LLP, issued a limited review report with no material misstatement noted. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Jul 2025 | credit rating Rating | Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Credit RatingAI summaryPiramal Pharma Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations dated 21 July 2025. CARE Ratings Limited upgraded the long-term bank facilities to CARE AA; Stable from CARE AA-; Positive. CARE upgraded the issuer rating and non-convertible debentures to CARE AA; Stable from CARE AA-; Positive. CARE reaffirmed the short-term bank facilities and commercial paper at CARE A1+. The long-term/short-term bank facilities were rated CARE AA; Stable / CARE A1+, with the outlook revised from Positive. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 May 2025 | transcript Results | Piramal Pharma Limited has informed the Exchange about TranscriptAI summaryPiramal Pharma Limited filed the transcript of its conference call held on 15 May 2025 on the audited standalone and consolidated financial results for the quarter and year ended 31 March 2025. The transcript is available on the company's website at piramalpharma.com/financial-reports. The filing is made under Regulation 30(6) of the SEBI (LODR) Regulations, 2015, in continuation of the company's letter dated 29 April 2025. The pages provided do not include the financial figures or the management remarks from the call. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2025 | presentation Guidance, Results | Piramal Pharma Limited has informed the Exchange about Investor PresentationAI summaryPiramal Pharma filed its press release and investor presentation on audited standalone and consolidated results for Q4 and FY ended 31 March 2025. Consolidated revenue from operations was ₹2,754 crore in Q4FY25 (up 8% YoY) and ₹9,151 crore in FY25 (up 12% YoY). Consolidated EBITDA was ₹603 crore in Q4FY25 (up 8%) and ₹1,580 crore in FY25 (up 15%), with EBITDA margin of 17% for FY25. Consolidated PAT after exceptional item was ₹91 crore for FY25, versus ₹18 crore in FY24; net debt to EBITDA improved to 2.7x from 5.6x in FY23. Chairperson Nandini Piramal said FY25 was a steady year, in line with annual guidance, and the company is on track for its FY2030 aspirations of $2bn revenue, 25% EBITDA margins and high-teens ROCE. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2025 | presentation Guidance, Results | Piramal Pharma Limited has informed the Exchange regarding a press release dated May 14, 2025, titled "Press Release and Investor Presentation Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year endAI summaryPiramal Pharma filed its press release and investor presentation on audited standalone and consolidated results for Q4 and FY2025 (quarter and year ended 31 March 2025), dated 14 May 2025. Consolidated FY25 revenue from operations was ₹9,151 crore, up 12% YoY; Q4FY25 revenue was ₹2,754 crore, up 8% YoY. Consolidated FY25 EBITDA was ₹1,580 crore (17% margin), up 15% YoY; FY25 net profit after exceptional items was ₹91 crore versus ₹18 crore in FY24. Net debt to EBITDA improved to 2.7x from 5.6x in FY23. Chairperson Nandini Piramal said FY25 was steady, in line with annual guidance, and the company remains on track for its FY2030 aspirations of $2bn revenue, 25% EBITDA margins and high-teens ROCE. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2025 | board outcome Dividend / buy-back, Management change, Results | Piramal Pharma Limited has informed the Exchange regarding Board meeting held on May 14, 2025.AI summaryPiramal Pharma's board on 14 May 2025 approved audited standalone and consolidated results for the quarter and year ended 31 March 2025. Standalone revenue from operations for FY2025 was Rs 5,285.71 crore and net profit after tax was Rs 691.40 crore; for Q4 FY2025 revenue was Rs 1,689.80 crore and net profit was Rs 277.27 crore. The board recommended a final dividend of Rs 0.14 per equity share (face value Rs 10), subject to shareholder approval at the 5th AGM. Nikhil... Neeraj Bharadwaj resigned as Non-Executive, Non-Independent Director (Carlyle representative) with immediate effect, citing personal commitments. Amit Jain was appointed as Additional Director (Non-Executive, Non-Independent) effective 14 May 2025, subject to shareholder approval; Jairaj Purandare was re-appointed as Non-Executive, Independent Director for a second five-year term from 9 February 2026, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2025 | dividend Dividend / buy-back, Management change, Results | Piramal Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of 0.14 per equity share.AI summaryOutcome of board meeting held on 14 May 2025: audited standalone and consolidated financial results for the quarter and year ended 31 March 2025 approved. Standalone for FY2025: revenue from operations Rs. 5,285.71 crore, net profit after tax Rs. 691.40 crore, basic EPS Rs. 5.22 (FY2024 net profit Rs. 391.22 crore). Standalone for Q4 FY2025 (quarter ended 31 March 2025): revenue from operations Rs. 1,689.80 crore, net profit after tax Rs. 277.27 crore. Board recommended a final dividend of Rs. 0.14 per equity share of Rs. 10 each for FY2025, subject to shareholder approval at the 5th AGM. Board approved resignation of Neeraj Bharadwaj as non-executive non-independent director, appointment of Amit Jain as additional non-executive non-independent director, and re-appointment of Jairaj Purandare as independent director for a second five-year term from 9 February 2026, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2025 | dividend Dividend / buy-back, Management change, Results | Piramal Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of Rs. 0.14 per equity share.AI summaryBoard of Piramal Pharma Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, on May 14, 2025. Standalone revenue from operations for FY2025 was Rs. 5,285.71 crores and net profit after tax was Rs. 691.40 crores, versus Rs. 4,390.11 crores and Rs. 391.22 crores in FY2024. Standalone net profit after tax for the quarter ended March 31, 2025 was Rs. 277.27 crores, and basic EPS for the year was Rs. 5.22. The Board recommended a final dividend of Rs. 0.14 per equity share of Rs. 10 each for FY2025, subject to shareholder approval at the 5th AGM. Board noted resignation of Neeraj Bharadwaj as non-executive non-independent director, appointed Amit Jain as additional director, and approved re-appointment of Jairaj Purandare as independent director for a second five-year term from February 9, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2025 | board outcome Dividend / buy-back, Management change, Results | Piramal Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.AI summaryPiramal Pharma's board on 14 May 2025 approved audited standalone and consolidated results for the quarter and year ended 31 March 2025. For Q4 FY25 (quarter ended 31 March 2025), standalone revenue from operations was Rs. 1,689.80 crore and net profit after tax was Rs. 277.27 crore; for FY25, revenue from operations was Rs. 5,285.71 crore and net profit after tax was Rs. 691.40 crore. The board recommended a final dividend of Rs. 0.14 per equity share (face value Rs. 10), payable after the 5th Annual General Meeting subject to shareholder approval. Neeraj Bharadwaj resigned as Non-Executive, Non-Independent Director (representing Carlyle) with immediate effect, citing personal commitments. The board appointed Amit Jain as Additional Director (Non-Executive, Non-Independent) from 14 May 2025, subject to shareholder approval, and re-appointed Jairaj Purandare as Non-Executive Independent Director for a second five-year term from 9 February 2026, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Apr 2025 | acquisition Acquisition | Piramal Pharma Limited has informed the Exchange about AcquisitionAI summaryPiramal Healthcare Inc., a step-down wholly owned subsidiary of Piramal Pharma Limited, entered a Stock Subscription Agreement and Loan Conversion Agreement dated April 23, 2025 to subscribe to 1,903 optionally convertible redeemable preference shares of face value USD 100,000 each of PPL Pharma Inc., aggregating USD 190,300,000 (Rs. 1,626.49 crore). Consideration comprises cash of USD 40,100,000 and conversion of an outstanding unsecured loan of USD 150,200,000 owed by PPL Pharma to Piramal Healthcare Inc. as on April 1, 2025. The filing describes the transaction as an exempted related party transaction at arm's length, with no change in the Company's holding in either entity, and says it is expected to complete in about 6 months. The transaction does not require any governmental or regulatory approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2025 | transcript | Piramal Pharma Limited has informed the Exchange about TranscriptAI summaryPiramal Pharma Limited filed the transcript of its conference call held on 29 January 2025 on the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024. The transcript is available on the company's website at piramalpharma.com/financial-reports. The filing itself contains no financial figures or management commentary; it is submitted under Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jan 2025 | results Results | Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024AI summaryPiramal Pharma Limited filed its unaudited standalone financial results for the quarter and nine months ended December 31, 2024, approved by the Board on January 28, 2025. Q3 FY25 revenue from operations was Rs. 1,248.32 crores, versus Rs. 1,024.14 crores in the corresponding quarter last year; profit after tax was Rs. 118.80 crores, versus Rs. 74.34 crores. Nine-month revenue from operations was Rs. 3,595.91 crores (Rs. 2,864.81 crores a year earlier); nine-month profit after tax was Rs. 414.13 crores (Rs. 118.14 crores). Basic EPS for the quarter was Rs. 0.90 (Rs. 0.56 a year earlier); nine-month basic EPS was Rs. 3.13 (Rs. 0.93). The statutory auditors, Deloitte Haskins & Sells LLP, carried out a limited review and issued a review report with no material misstatement noted. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jan 2025 | presentation Results | Piramal Pharma Limited has informed the Exchange about Investor PresentationAI summaryPiramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2024. Consolidated revenue from operations was ₹2,204 Cr in Q3FY25 (up 13% YoY) and ₹6,397 Cr in 9MFY25 (up 14% YoY); 9MFY25 EBITDA was ₹977 Cr (up 20% YoY) with EBITDA margin of 15%. Consolidated net profit after tax was ₹4 Cr in Q3FY25 (down 64% YoY) and a loss of ₹(62) Cr in 9MFY25. Management (Chairperson Nandini Piramal) said FY25 has been a steady year, with CDMO revenue up 18% in 9MFY25 and ICH power brands growing about 19%. The company stated its Net-Debt to EBITDA ratio was maintained at 2.8x, and an earnings conference call is scheduled for 29 January 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jan 2025 | board outcome Management change, Results | Piramal Pharma Limited has informed the Exchange regarding Board meeting held on January 28, 2025.AI summaryBoard of Piramal Pharma Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024 on 28 January 2025. Standalone revenue from operations for Q3 FY25 was Rs. 1,248.32 crores versus Rs. 1,024.14 crores in the corresponding quarter last year; standalone profit after tax was Rs. 118.80 crores versus Rs. 74.34 crores. Standalone profit after tax for the nine months ended 31 December 2024 was Rs. 414.13 crores versus Rs. 118.14 crores in the previous corresponding period. The Board appointed Ms. Nathalie Leitch (DIN: 09557042) as an Additional Director (Non-Executive, Non-Independent) with effect from 28 January 2025, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jan 2025 | results Management change, Results | Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryBoard of Piramal Pharma Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024 on 28 January 2025. Standalone revenue from operations for Q3 FY25 (quarter ended 31 Dec 2024) was Rs. 1,248.32 crores, against Rs. 1,024.14 crores in the corresponding quarter last year; standalone profit after tax was Rs. 118.80 crores versus Rs. 74.34 crores. For the nine months ended 31 Dec 2024, standalone revenue from operations was Rs. 3,595.91 crores and profit after tax was Rs. 414.13 crores (basic EPS Rs. 3.13). The Board appointed Ms. Nathalie Leitch (DIN: 09557042) as an Additional Director (Non-Executive, Non-Independent) with effect from 28 January 2025, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.